## Review setup
- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract; no figures, methods, or supplementary materials were provided
- **Shared manuscript claim summary** The authors present Deep-Phase, a neural-network framework that quantifies condensate morphology changes from microscopy images, links these changes to drug-induced perturbations of rRNA transcription and processing in the nucleolus, identifies a new nucleolar morphology in a chemical screen, and proposes a role for a DNA topoisomerase in rRNA processing. The framework is claimed to be adaptable across cell lines, labeling techniques, and condensate types.
- **Visible evidence base** Abstract text only; no figures, tables, methods, or statistical details
- **Missing materials affecting confidence** Full manuscript, figures, methods, validation datasets, code availability, and statistical analyses

## Reviewer
- **Overall assessment** The abstract describes a potentially valuable computational tool for linking condensate morphology to biochemical function, with a demonstrated application to nucleolar biology and drug screening. However, the abstract alone provides insufficient detail to evaluate the technical soundness of the neural-network approach, the robustness of the morphological quantification, or the strength of the biological claims. The claim regarding a DNA topoisomerase role in rRNA processing is particularly under-supported in the absence of mechanistic data. The work is likely of interest to the condensate biology and drug discovery communities, but the case is not fully established from the supplied material.
- **Who would be interested in the results, and why** Researchers studying biomolecular condensates, nucleolar biology, and RNA processing would be interested in the morphological readout and its link to biochemical perturbations. Drug discovery scientists may find the screening application appealing as a phenotypic assay platform. Computational biologists developing image-based deep learning tools for cellular structures would also be a relevant audience.
- **Major strengths** The conceptual advance of using condensate morphology as a functional readout is timely and potentially impactful. The demonstrated application to a chemical screen and the identification of a previously unrecognized nucleolar morphology suggest the framework can generate new biological hypotheses. The claimed adaptability across cell lines, labeling techniques, and condensates, if validated, would broaden the utility of the approach.
- **Major Concerns** 
  - R1-M1
  - R1-M2
  - R1-M3
- **Minor Comments** 
  - R1-m1
  - R1-m2
  - R1-m3
- **Technical failings that need to be addressed before the case is established** The abstract does not provide details on model architecture, training data size, validation against ground truth, or statistical methods for quantifying morphology changes. The mechanistic claim for DNA topoisomerase in rRNA processing is not supported by any presented evidence. The generalizability claim is stated but not substantiated with specific examples or quantitative metrics.
- **Assessment against Nature-style criteria** Originality is high, as the approach of using deep learning on condensate morphology as a functional readout is novel. Scientific importance is potentially high for condensate biology and drug screening, but the significance depends on the robustness of the morphological quantification and the biological validity of the topoisomerase finding. Interdisciplinary readership is plausible, spanning cell biology, computational biology, and pharmacology. Technical soundness cannot be assessed from the abstract alone, as no methodological details or validation metrics are provided. Readability for nonspecialists is adequate, though the abstract assumes familiarity with condensate biology and deep learning terminology.
- **Recommendation posture** Supportive if technical concerns are resolved, but currently not established from the provided evidence. The abstract presents a promising framework, but the lack of methodological detail and the under-supported biological claims require full manuscript evaluation.

### Major Concerns

- **Concern ID** R1-M1
- **Severity** Major
- **Blocking** Yes
- **Axis** Technical soundness
- **Claim pointer** The neural-network framework Deep-Phase uses microscopy images to directly measure condensate morphology changes resulting from pharmacological alterations.
- **Evidence pointer** Abstract; location not provided
- **Concern** The abstract does not describe the architecture, training procedure, or validation of the neural network. No metrics are provided for the accuracy, precision, or reproducibility of the morphological measurements. Without these details, it is impossible to assess whether the framework reliably quantifies morphology changes or whether the results could be artifacts of the model.
- **Why it matters** The central claim of the paper rests on the reliability of Deep-Phase as a measurement tool. If the model is not properly validated against independent ground truth or if the training data are biased, all downstream biological conclusions could be compromised.
- **Resolution test** Provide details on model architecture, training and test datasets, validation against manual or orthogonal measurements, and error analysis. Include quantitative metrics such as correlation coefficients, precision-recall curves, or segmentation accuracy.

- **Concern ID** R1-M2
- **Severity** Major
- **Blocking** Yes
- **Axis** Biological claim support
- **Claim pointer** Mechanistic studies of this morphology provide insights into how the interfaces between nucleolar sub-compartments are maintained, and a role for a DNA topoisomerase in rRNA processing is identified.
- **Evidence pointer** Abstract; location not provided
- **Concern** The abstract states that a DNA topoisomerase plays a role in rRNA processing, but no mechanistic data are presented. The nature of the evidence, whether genetic, pharmacological, or biochemical, is not specified. The claim that interfaces between nucleolar sub-compartments are maintained is also vague without supporting molecular details.
- **Why it matters** These are strong biological claims that go beyond the descriptive morphological analysis. If the evidence is only correlative or based on a single assay, the conclusions would be premature. The significance of the work depends on the validity of these mechanistic insights.
- **Resolution test** Present the specific experiments that link the DNA topoisomerase to rRNA processing, including controls and statistical significance. Clarify the mechanistic model for how nucleolar sub-compartment interfaces are maintained and provide direct evidence for this model.

- **Concern ID** R1-M3
- **Severity** Major
- **Blocking** No
- **Axis** Generalizability
- **Claim pointer** Deep-Phase's adaptability to diverse cell lines, labeling techniques, and condensates is demonstrated.
- **Evidence pointer** Abstract; location not provided
- **Concern** The abstract claims broad adaptability but does not specify which cell lines, labeling techniques, or condensate types were tested, nor does it provide quantitative comparisons of performance across these conditions. The claim may be overstated if the tests were limited in scope.
- **Why it matters** The utility of Deep-Phase as a general platform depends on its performance across varied experimental contexts. If the adaptability is only demonstrated in a narrow set of conditions, the claim of a powerful platform is not fully justified.
- **Resolution test** Provide a table or figure summarizing the tested conditions, with performance metrics for each. Discuss any limitations or conditions where the framework underperforms.

### Minor Comments

- **Concern ID** R1-m1
- **Severity** Minor
- **Axis** Clarity
- **Affected element** Terminology
- **Evidence pointer** Abstract; location not provided
- **Issue** The term "Deep-Phase" is introduced with a parenthetical explanation, but the relationship between the name and the method is not immediately clear. The abstract could benefit from a brief statement of what the network predicts or segments.
- **Required correction** Add one sentence clarifying the input and output of the network, such as whether it segments condensate boundaries or classifies morphology states.

- **Concern ID** R1-m2
- **Severity** Minor
- **Axis** Quantitative detail
- **Affected element** Drug potency correlation
- **Evidence pointer** Abstract; location not provided
- **Issue** The abstract states that morphological perturbations are "tightly coupled" to drug potencies, but no correlation coefficients or statistical measures are provided.
- **Required correction** Include a quantitative measure, such as an R-squared value or p-value, to support the strength of the coupling.

- **Concern ID** R1-m3
- **Severity** Minor
- **Axis** Reproducibility
- **Affected element** Code and data availability
- **Evidence pointer** Abstract; location not provided
- **Issue** No mention is made of code or data availability, which is important for a computational framework.
- **Required correction** State in the abstract or methods whether the code and training data will be made publicly available.

## Risk / unsupported claims
- The claim that Deep-Phase "directly measures" morphology changes is unsupported without validation details.
- The identification of a role for a DNA topoisomerase in rRNA processing is unsupported from the abstract alone.
- The claim of adaptability to diverse cell lines, labeling techniques, and condensates is unsubstantiated without specific examples and metrics.
- The statement that morphological perturbations are "tightly coupled" to drug potencies is unquantified and thus not assessable.